dm+d
406785006
Medicine Compliance Aid Stability
AbilifyOtsuka Pharmaceuticals UK Ltd
Otsuka Pharmaceuticals UK Ltd
Abilify
Tablets 5mg, 10mg, 15mg, 30mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from moisture
Hygroscopic protect from moisture and light. Maximum of 7 days in MCA
25 October 2022
Abilify OrodispersibleOtsuka Pharmaceuticals UK Ltd
Otsuka Pharmaceuticals UK Ltd
Abilify Orodispersible
Tablets orodispersible 10mg, 15mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from moisture. Orodispersible in nature therefore likely to be hygroscopic.
10 January 2022
generic (Caduceus)Actavis UK Ltd
Actavis UK Ltd
generic (Caduceus)
Tablets orodispersible 10mg, 15mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from moisture. Orodispersible in nature therefore likely to be hygroscopic.
18 January 2023
genericAurbindo Pharma
Aurbindo Pharma
generic
Tablets 5mg, 10mg, 15mg, 30mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from light
Protect from light. Maximum of 7 days in MCA.
3 November 2022
Lactation Safety Information
Oral / depot injection
Oral / depot injection
Quetiapine, Haloperidol
Very limited published evidence shows that maternal doses up to 15mg daily produce low levels in breast milk
Long half-life increases risk of accumulation in breastfed infants
Anecdotal unpublished reports of somnolence in breastfed infants
Monitor infant for sedation, poor feeding, behavioural effects, extrapyramidal symptoms, and developmental milestones
Possible effect on prolactin may decrease milk supply
22 January 2020